BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE announced a quarterly dividend on Tuesday, August 6th. Stockholders of record on Friday, August 16th will be given a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported $1.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.08. The biotechnology company earned $191.66 million during the quarter, compared to the consensus estimate of $196.37 million. BIO-TECHNE had a net margin of 13.45% and a return on equity of 13.20%. The company's revenue was up 6.3% on a year-over-year basis. During the same period last year, the firm posted $1.34 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 equities research analysts have issued 12-month target prices for BIO-TECHNE's stock. Their predictions range from $165.00 to $270.00. On average, they expect BIO-TECHNE's stock price to reach $206.80 in the next year. This suggests a possible upside of 2.1% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Press coverage about TECH stock has been trending very negative on Thursday, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIO-TECHNE earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 799,800 shares, an increase of 8.1% from the August 15th total of 739,700 shares. Based on an average daily trading volume, of 166,700 shares, the days-to-cover ratio is presently 4.8 days. Currently, 2.1% of the shares of the company are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Amgen (AMGN), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH) and Illumina (ILMN).

BIO-TECHNE's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.05%), Summit Creek Advisors LLC (0.22%), Palisade Asset Management LLC (0.04%), Pacer Advisors Inc. (0.04%), Tributary Capital Management LLC (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Pacer Advisors Inc., Palisade Asset Management LLC and Crossmark Global Holdings Inc.. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was acquired by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, State of Alaska Department of Revenue, Tributary Capital Management LLC, Navellier & Associates Inc, Clarus Wealth Advisors and Diversified Trust Co. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $202.48.

BIO-TECHNE has a market capitalization of $7.67 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]